Tilray Brands (NASDAQ: TLRY)
Tilray Brands Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Tilray Brands Company Info
Tilray Brands, Inc. is a global cannabis-lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America. The firm is focused on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. Its products include dried cannabis and cannabis extracts. It operates through the following segments: Cannabis and Hemp. The Cannabis segment consists of adult-use, medical and bulk sales of cannabis under regulated licenses and sold to retail, wholesale, pharmacy, government, and direct to patient. The Hemp segment consists of hemp seed, hemp foods, and broad spectrum hemp extract containing CBD, which are sold in an unlicensed operation and sold to retail, wholesale and direct to consumers. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.
News & Analysis
Why Investors Were Fired Up About Tilray Stock Today
Yes, the wacky weed has good and positive healthcare uses too.
Why Tilray Brands Stock Just Stubbed Out
Temporarily profitable Tilray is taking advantage of its chance to raise some cash.
Stock Market Today: Tilray Brands Soars After Earnings Beat
Tilray Brands surged after posting stronger-than-expected quarterly results and renewed optimism around U.S. cannabis reform.
Why Tilray Brands Stock Glows Green Today
Tilray surprised marijuana investors once today. Can it do it again?
Is Now the Time to Finally Buy Pot Stocks Again?
The potential for cannabis reform has made investors bullish on the industry in recent weeks.
Why Tilray Stock Leaped 8% Higher on Tuesday
The case for de facto marijuana legalization is growing, albeit slowly.
Should You Buy Tilray Brands Stock Before Oct. 9?
Tilray Brands reports earnings next week, which could determine whether its recent rally holds up.
Why Tilray Brands Soared 40% This Week
President Trump appeared to endorse CBD and having Medicare cover it, while cannabis de-scheduling remains a possibility.
Valuation
Earnings Transcripts
Tilray (TLRY) Q1 2026 Earnings Call Transcript
None
Tilray (TLRY) Q4 2025 Earnings Call Transcript
None
Tilray Brands (TLRY) Q2 2025 Earnings Call Transcript
TLRY earnings call for the period ending December 31, 2024.
Tilray Brands (TLRY) Q1 2025 Earnings Call Transcript
TLRY earnings call for the period ending September 30, 2024.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.